OMKAR PHARMACHEM LTD.

Omkar Pharmachem Limited has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading Regulations), 2015, and the company's internal code of conduct. The trading window will be shut from July 01, 2026, until 48 hours after the declaration of the company's Unaudited Financial Results for the quarter ended June 30, 2026. The date for the board meeting to approve these results will be announced separately.

Omkar Pharmachem Ltd's board meeting on May 30, 2026, approved the audited financial results for the quarter and year ended March 31, 2026. The meeting commenced at 05:00 P.M. and concluded at 05:40 P.M. The results have been audited by Dipal R. Shah & Co., who have issued an independent auditor's report stating that the financial results give a true and fair view in conformity with applicable accounting standards.

Omkar Pharmachem Ltd has announced its audited financial results for the quarter and year ended March 31, 2026. The results, along with the auditor's report, statement of assets and liabilities, cash flow statement, and declaration under Regulation 33(3)(d) of SEBI Regulations 2015, were approved by the Board of Directors in their meeting held on May 30, 2026. The audit was conducted by DIPALR. SHAH & CO., who issued an independent auditor's report stating that the financial results give a true and fair view in conformity with Indian Accounting Standards.

Omkar Pharmachem Ltd has scheduled a Board of Directors meeting on May 30, 2026, to consider and approve the audited financial results for the quarter and financial year ended March 31, 2026. The trading window for dealing in the company's shares will remain closed until June 01, 2026, for designated persons and their immediate relatives.

Omkar Pharmachem Ltd has announced a change in the name of its Managing Director, Bhawani Shankar Goyal, to Bhawani S Goyal, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board of Directors has acknowledged the change, clarifying that it solely involves the name and does not affect the designation, role, or responsibilities of the Managing Director.

Omkar Pharmachem Ltd has submitted a clarification regarding the delay in filing the cessation of Independent Director, Mr. Janak Raj Sharma's, term. The delay was due to a misunderstanding about the timing of the intimation. The matter was placed before the Board and noted at the Board Meeting held on 14.02.2026, and the intimation was then duly filed on the same date.

Omkar Pharmachem Ltd has reported its unaudited financial results for the quarter and nine months ended on 31st December 2025. The company's revenue from operations stands at Rs. 1,008.37 lakhs for the quarter and Rs. 3,794.00 lakhs for the nine months period. The total expenses for the quarter are Rs. 1,065.00 lakhs and Rs. 3,964.22 lakhs for the nine months period. The company reported a profit before tax of Rs. 4.22 lakhs for the quarter and Rs. 100.15 lakhs for the nine months period. The earning per share (EPS) before and after extraordinary items is Rs. 6.91 and Rs. 18.48 respectively.

Omkar Pharmachem Ltd. has approved the unaudited financial results for the quarter and nine months ended on 31st December, 2025. The company's total income stands at Rs. 4,072 lakhs and Rs. 5,422 lakhs respectively. The profit before tax for the quarter and nine months is Rs. 1,372 lakhs and Rs. 1,030 lakhs respectively. The company's total expenses for the quarter and nine months are Rs. 3,094 lakhs and Rs. 4,382 lakhs respectively. The company's earnings per share before and after extraordinary items for the quarter is Rs. 0.22 and Rs. 0.1059 respectively. The company's earnings per share before and after extraordinary items for the nine months is Rs. 0.2205 and Rs. 0.0293 respectively.

Omkar Pharmachem Ltd has processed and approved share transfer requests under the special window provided by the SEBI Circular dated 2nd July 2025. The report includes the status of requests received, processed, approved, and rejected from 1st January 2026 to 6th January 2026.

Omkar Pharmachem Ltd has released a report on shares relodged for transfer cum demat during the month of December 2025. This report is in accordance with the SEBI Circular No. SESI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97 dated July 2, 2025. The report provides details of the requests received from shareholders for the re-lodgement of transfer requests for physical shares under the special window provided by the SEBI Circular.